Data of safety in a single-center alemtuzumab treated population

Vincenzo Di Stefano, Maria Di Ioia, Daniela Travaglini, Giovanna De Luca, Valeria Di Tommaso, Erika Pietrolongo, Vincenzo Di Stefano, Stefano L. Sensi, Deborah Farina, Marco Onofrj

Risultato della ricerca: Articlepeer review

Abstract

Alemtuzumab is approved for highly active MS and, in Europe, can be employed after other disease-modifying treatments (DMTs) as an escalation approach or first therapeutic option. The occurrence of secondary autoimmune adverse events and infections differs depending on the employed approach. In the manuscript entitled “Alemtuzumab treatment of multiple sclerosis in real-world clinical practice: report from a single Italian center” by di Ioia M. and collaborators, efficacy and safety data of alemtuzumab were evaluated in a real-world MS population. The aim of the article is to describe in detail the unexpected serious adverse events which occurred in this cohort during and after the administration of the alemtuzumab treatment. Adverse events were observed in 45,7% of the patients. These events were ranked as severe in 23% of the patients. We reported, in particular, cases of autoimmune hemolytic anemia (AIHA), pancytopenia, viral hepatitis E and noninfectious meningo-encephalomyelitis.
Lingua originaleEnglish
pagine (da-a)1-3
Numero di pagine3
RivistaData in Brief
Volume29
Stato di pubblicazionePublished - 2020

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.1000???

Cita questo